Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
XRCC3
REST API REST API
Homo sapiens
XRCC3 is differentially expressed in 185 experiments: 67 organism parts: bone marrow, blood, ... (65 more);, 121 disease states: normal, glioblastoma, ... (119 more);, 41 cell types 252 cell lines 27 compound treatments and 64 other conditions.
Orthologs XRCC3_BOVIN (Bos taurus)   Q5ZM26_CHICK (Gallus gallus)   LOC100359601 (Rattus norvegicus)   Xrcc3 (Mus musculus)   xrcc3 (Danio rerio)   RAD57 (Saccharomyces cerevisiae)   spn-B (Drosophila melanogaster)   xrcc3 (Xenopus laevis)   XRCC3 (Canis familiaris)   (Compare orthologs)
InterPro Term DNA_recomb_RecA/RadB_ATP-bd, DNA_recomb/repair_RecA-like, DNA_recomb/repair_Rad51_C
Gene Ontology Term DNA binding, DNA repair, cytoplasm, ATP binding, DNA-dependent ATPase activity, nucleus, DNA recombination, nucleotide binding, perinuclear region of cytoplasm, response to DNA damage stimulus, DNA metabolic process, mitochondrion
UniProt Accession Q53XC8, O43542
Gene-Disease Assocation BREAST CANCER, MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 6; CMM6
Search EB-eye ENSG00000126215
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MEXP-433, E-MTAB-25, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (30 experiments)

Factor Value U/D Experiments
HT1080
2
E-MTAB-37, E-GEOD-20089
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
MCF-7
1
2
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081
MDA-MB-231
1
2
E-TABM-420, E-GEOD-5823, E-MTAB-62
primary culture
1
E-GEOD-1657
246 more value(s).


Cell type

studied in E-GEOD-18811, E-AFMX-5, E-GEOD-19069, E-GEOD-20033, E-GEOD-1460, ... (22 experiments)

Factor Value U/D Experiments
centroblast
1
E-GEOD-15271
fetal RPE
1
E-GEOD-18811
primary lymphatic endothelial cell
1
E-MEXP-66
cardiac myocyte
1
E-AFMX-5
CD19+ B cell
1
E-MEXP-1600
endothelial cell
1
E-GEOD-3998
35 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-1577, E-GEOD-9692, ... (37 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-57
glioblastoma
1
2
E-GEOD-4290, E-MTAB-37, E-MEXP-567
normospermic
1
E-GEOD-6872
Ewings Sarcoma
1
E-MTAB-62
carcinoma in situ, bladder tumor
1
E-MTAB-62
115 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, ... (14 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
Cxcl12
1
E-GEOD-7307
4,5-dianilinophthalimide
1
1
E-GEOD-5258
mercaptopurine, methotrexate
1
E-GEOD-412
nocodazole
1
E-GEOD-571
TNF
1
E-GEOD-15205
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-MEXP-421, E-TABM-868, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, E-GEOD-9764, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-666, E-GEOD-6919, ... (23 experiments)

Infection
studied in E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-2487 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-4922

Processing time: 0.265 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM